Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04638764
Other study ID # GH-MS-CVD-RT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 23, 2020
Est. completion date November 26, 2021

Study information

Verified date November 2020
Source General Hospital Murska Sobota
Contact Mitja Lainšcak, MD, PhD
Phone +386 (0)2 5123733
Email mitja.lainscak@guest.arnes.si
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study coronary artery disease patients and patients with heart failure will be randomly assigned to three training groups: combined aerobic interval training with high intensity resistance training, combined aerobic interval training with low intensity resistance training and aerobic interval training.


Description:

Exercise-based cardiac rehabilitation programmes have predominantly used aerobic-dynamic exercise modalities, whereas resistance training have been discouraged in patients with cardiovascular disease, due to safety concerns related to cardiovascular response (heart rate and blood pressure) during the exertion. Contrary to such concerns, recent hemodynamic studies have reported lower blood pressure and heart rate during higher intensity resistance training (>70 % 1-RM) compared to lower intensity resistance training (>40 % 1-RM). Furthermore, the latest meta analysis have demonstrated that combined resistance training with standard aerobic interval training has been superior than aerobic training alone in several aspects of health. However, there is still huge heterogeneity in training intervention design, also there still lacks studies to further elucidate the effects of high intensity resistance training combined with aerobic training on physical performance (aerobic capacity, muscle strength, balance), body composition, quality of life, morbidity, mortality, etc. Therefore, the aim of this study was to examine the effects of high (70%-80 % 1-RM) versus low loads (30%- 40 % 1-RM) resistance training in combination with aerobic interval cycling (50 % -80% of baseline peak Power output) in coronary artery disease patients and patients with heart failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date November 26, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Stable patients with documented CAD with clinical event (>1 month after acute coronary syndrome and/or percutaneous coronary intervention) or coronarography and/or - Stable Heart Failure patients with documented reduced ejection fraction (>40-45 %) - age >18 years - NYHA class I-III - Cardiopulmonary exercise test without ECG abnormalities Exclusion Criteria: - Unstable CHD - Decompensated HF - Uncontrolled arrhythmias - Severe and symptomatic aortic stenosis - Acute myocarditis, endocarditis, or pericarditis - Aortic dissection - Marfan syndrome - Musculoskeletal limitations

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Aerobic interval training combined with high intensity resistance training
Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
Aerobic interval training combined with low intensity resistance training
Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
Aerobic interval training
Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).

Locations

Country Name City State
Slovenia Division of Cardiology, General Hospital Murska Sobota Murska Sobota

Sponsors (3)

Lead Sponsor Collaborator
General Hospital Murska Sobota University of Ljubljana, Faculty of Sport, University of Primorska

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Maximal aerobic capacity Measured as change in VO2 max (ml/kg/min) Change in maximal aerobic capacity at 12 weeks compared to baseline
Primary Change in Maximal voluntary contraction of knee extensors Measured as change in maximal isometric torque of knee extensors Change in maximal isometric torque at 12 weeks compared to baseline
Secondary Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Measured as change in HOMA IR (%) Change in HOMA-IR at 12 weeks compared to baseline
Secondary Change in glucose levels Measured as change in glucose levels (mmol/L) Change in glucose levels at 12 weeks compared to baseline
Secondary Change in insulin levels Measured as change in insulin levels Change in insulin levels at 12 weeks compared to baseline
Secondary Change in systolic blood pressure during high and low load resistance exercise Measured as change in systolic blood pressure during resistance exercise compared to baseline (pre-exercise) values Change of systolic blood pressure during resistance exercise compared to baseline (pre-exercise) within the first and the last week of the intervention
Secondary Change in diastolic blood pressure during high and low load resistance exercise Measured as change in diastolic blood pressure during resistance exercise compared to baseline (pre-exercise) Change of diastolic blood pressure during resistance exercise compared to baseline (pre-exercise) within the first and the last week of the intervention
Secondary Change in heart rate during high and low load resistance exercise Measured as change in heart rate during resistance exercise compared to baseline (pre-exercise) Change of heart rate during resistance exercise compared to baseline (pre-exercise) within the first and the last week of the intervention
Secondary Change in rating of perceived exertion during high and low load resistance exercise Measured as change of rating of perceived exertion (0-10) during resistance exercise compared to baseline (pre-exercise) Change of rating of perceived exertion (score 0-10, 0-no exertion, 10-maximal exertion) during resistance exercise compared to baseline (pre-exercise) within the first and the last week of the intervention
Secondary Change in Short Physical Performance Battery (SPPB) total score Measured as change in points of the SPPB after 12 weeks compared to baseline Change in the Short Physical Performance battery test total score (0-the worse outcome, 12- the best outcome) after 12 weeks compared to baseline
Secondary Change in time of the "Up and Go" test Measured as change of time (s) in "Up and Go" test Change in seconds of the "Up and Go" test after 12 weeks compared to baseline
Secondary Change in Grip strength test (kg) Measured as change of kg in Grip strength test Change in kg of Grip strength test after 12 weeks compared to baseline
Secondary Change in Arm curl test (number of repetitions) Measured as change of number of repetitions in Arm curl test Change in number of repetitions of the Arm curl test after 12 weeks compared to baseline
Secondary Change in time of the Sit to stand test Measured as change in time (s) of the Sit and stand test Change in seconds of the Sit to stand test after 12 weeks compared to baseline
Secondary Change in One Leg Heel Raise test (number of repetitions) Measured as change of number of repetitions in One leg heel raise test Change in number of repetitions of One leg heel raise test after 12 weeks compared to baseline
Secondary Change in total energy expenditure Measured as change in kcal using accelerometry data Change in kcal after 12 weeks compared to baseline
Secondary Change in sedentary activity level Measured as change in minutes spent in sedentary activity level using accelerometry data Change in minutes of sedentary activity after 12 weeks compared to baseline
Secondary Change in moderate to vigorous physical activity level Measured as change in minutes spent in moderate to vigorous physical activity level using accelerometry data Change in minutes of moderate to vigorous physical activity after 12 weeks compared to baseline
Secondary Change in the Back Scratch test Measured as change in cm of the Back Scratch test Change in cm of the Back Scratch test after 12 weeks compared to baseline
Secondary Change in the Chair Sit and Reach test Measured as change in cm of the Chair Sit and Reach test Change in cm of the Chair sit and Reach test after 12 weeks compared to baseline
Secondary Change in Stork balance test Measured as change in seconds of the Stork balance test Change in seconds of the Stork balance test after 12 weeks compared to baseline
Secondary Change in Short form Health related quality of life questionnaire (SF-12) Measured as change in score of the SF-12 Change in score of the Short form 12 items health related questionnaire (12 points -the lowest score, 47 points the highest score) after 12 weeks compared to baseline
Secondary Change in Patients health questionnaire score (PHQ-9) Measured as change in points of PHQ-9 questionnaire Change in score of the Patients health 9-item questionnaire (0 points-the best outcome, 27 points-the worse outcome) after 12 weeks compared to baseline
Secondary Change in Respiratory Exchange Ratio (RER) Measured as percent change of RER during cardiopulmonary exercise test Change in % after 12 weeks compared to baseline
Secondary Change in Ve/VCO2 slope ratio Measured as change in VE/VCO2 slope Change in ratio of VE/VCO2 slope after 12 weeks compared to baseline
Secondary Change in Tumor necrosis factor alpha (TNF-alpha) level Measured as change in TNF-alpha Change in TNF-alpha level after 12 weeks compared to baseline
Secondary Change in Interleukin 6 (IL-6) level Measured as change in IL-6 level Change in IL-6 level after 12 weeks compared to baseline
Secondary Change in Human Growth hormone (hGH) level Measured as change in hGH level Change in hGH level after 12 weeks compared to baseline
Secondary Change in Insulin like Growth Factor 1 (IGF-1) Measured as change in IGF-1 level Change in IGF-1 level after 12 weeks compared to baseline
Secondary Change in N-terminal-pro brain natriuretic peptide (NT-proBNP) Measured as change in NT-proBNP level Change in NT-proBNP level after 12 weeks compared to baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A